This resolution declares the sense of the House of Representatives that the Federal Government has a duty to lead the world in biomedical research. It highlights the historical success of the model of federal funding, particularly through the National Institutes of Health (NIH), in driving unprecedented increases in medical knowledge and breakthroughs since World War II. Federal investment has been crucial for supporting basic research that is often too early-stage, risky, or complex for private industry, underpinning nearly every new drug approved by the Food and Drug Administration in the 21st century.

The resolution asserts that the United States' biomedical research and development capacity is a vital national asset that must be protected, improved, and expanded. It emphasizes that federal efforts, especially through the NIH, ensure a robust research apparatus and maintain the U.S. global leadership in biomedical innovation. Furthermore, it calls for treating the biomedical research workforce with respect, offering good pay and benefits, and ensuring that scientific decision-making is evidence-driven, peer-reviewed, and insulated from political interference.

To further these goals, the resolution proposes that the Federal Government should double its investment in biomedical research over the next decade. This investment should support a wide range of research, including basic science to understand the human body, studies clarifying disease root causes, translational science to accelerate novel treatments, and high-risk, high-reward projects. The resolution also outlines specific health challenges that federal research should address, such as reversing declining U.S. life expectancy, developing responses to microbial threats, combating neurodegenerative diseases, reducing cancer and Alzheimer's burdens, and improving health equity by ensuring representation in clinical trials.